IMAGE RESPONSE ASSESSMENT

在临床前和临床转化研究中，影像学在非侵入性评估癌症生物学方面发挥着越来越重要的作用。在临床实践中，成像技术正被用于个性化治疗。在癌症治疗的早期和晚期临床试验中，成像可以提供治疗作用机制的关键信息，包括靶点是否存在，靶点是否被治疗“击中”，癌症是否有反应以及肿瘤是否发生进展。这些测量的元素是JHU的Sidney kimmel癌症中心进行的许多涉及癌症治疗的研究的重要组成部分。定性成像现在正由复杂的定量方法加以补充。为了确保获得先进的成像技术，包括定量PET， MRl和CT， SKCC内建立了成像反应评估实验室（IRAT）。IRAT最初是作为CCSG的一个有竞争力的NCI补充而建立的，现在正在转变为癌症中心研究人员可用的核心服务。IFWVT向SKCC调查人员提供的服务包括：a)关于临床试验中影像学研究的正确选择、设计和使用的咨询和指导，b)临床方案的专家评审，以确保影像学方案和分析计划适合所选择的任务，c)使用标准化的解剖和代谢反应标准（包括RECIST 1.1、PERCIST 1.0）及时准确地评估肿瘤反应，d)图像存档、匿名化和数据导入/导出，e)编写文件。协助在一个或多个地点进行研究的协议和表格，g)关于辐射暴露和分子显像剂的监管指导，以及h)改善癌症中心研究人员和定量成像专家之间的合作。未来的计划包括确保计算和软件平台的更新，以继续使用当前和新兴的成像工具为癌症治疗反应的单模式和多模式成像研究提供可靠的定量分析。IRAT输入到研究设计和分析中，有望在JHU和其他机构合作进行的癌症治疗研究中获得更合适、更准确和可重复的成像。适当的定量成像应有利于临床癌症治疗试验的各个阶段，并应加快转化癌症的研究。雷：为了有效地治疗癌症，为了测试和评估新的治疗方法，对癌症的位置、大小和生物学特征进行精确的非侵入性定量成像是必不可少的。IFJAT核心使用PET， MRl， CT和其他工具来评估肿瘤，确定它们是否可能对治疗有反应，并快速准确地量化肿瘤是否适合给定的治疗，是否对治疗有反应或没有反应

Imaging plays a major and growing role in non-invasively assessing cancer biology both pre-clinically and in clinical translational studies. Imaging is now being used to personalize therapies in clinical practice. In early and advanced clinical trials of cancer therapeutics, imaging can provide key information on the mechanisms of action of the treatment, including whether targets are present, whether the target is "hit" by the therapy, whether the cancer is responding and if tumor progression has occurred. Elements of such measurements are an important part of many studies involving cancer therapy conducted at the Sidney Kimmell Cancer Center at JHU. Qualitative imaging is now being complemented by sophisticated quantitative approaches. To assure access to advanced imaging technologies including quantitative PET, MRl, and CT the Imaging Response Assessment Laboratory (IRAT) has been established within the SKCC. The IRAT was first established as a competitive NCI supplement to the CCSG, and is now being transitioned to a Core service available to cancer center investigators. Services of the IFWVT available to SKCC investigators include: a) Consultation and guidance on the proper choice, design and use of imaging studies in clinical trials, b) Expert reviews of clinical protocols to assure that the imaging protocol and analysis plans are appropriate for the chosen task, c) State of the art prompt and accurate assessment of tumor response using standardized anatomic and metabolic response criteria, including RECIST 1.1, PERCIST 1.0, d) Image archival, anonymization, and data import / export, e) Developing documents, protocols and forms to assist in studies performed at one or multiple sites, g) Regulatory guidance on radiation exposure and molecular imaging agents, and h) Improving collaborations among cancer center investigators and imaging specialists in quantitative imaging. Future plans include assuring computing and software platforms are updated to continue to provide robust quantitative analyses of single and multimodal imaging studies of cancer treatment response with current and emerging imaging tools. IRAT input into study design and analysis is expected to lead to more appropriate, accurate and reproducible imaging in cancer therapy studies performed at JHU and in collaboration with other institutions. Appropriate quantitative imaging should benefit clinical cancer therapy trials of all phases and should accelerate translational cancer research. Lay: For cancers to be treated effectively and for new treatments to be tested and evaluated, precise non-invasive quantitative imaging of the location, size and biological characteristics of the cancers is essential. The IFJAT core uses PET, MRl, CT and other tools to evaluate tumors, determine if they are likely to respond to treatment and quantifies quickly and accurately whether the tumors are suitable for a given treatment, are responding to treatment or are failing to respond